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similar vein, screening instruments for depression were once
designed for use in the general population and evaluated as such
[10], while in medical patients, such instruments are known to beIn the review by Poole and colleagues in this issue of Journal of
Psychosomatic Research, it is suggested that depression that develops
in the aftermath of an acute coronary syndrome (ACS), such as a
myocardial infarction (MI), may have a different etiology than
depression as is observed in the general population. Interestingly,
the authors make a case that post-MI depression results from
inﬂammatory processes that surround the MI [1].
The review ﬁts well in the growing attention for the phenotypical
heterogeneity of major depression which is observed both in general
psychiatry and in the psychosomatic ﬁeld (e.g., [2–5]). For instance,
Lux and Kendler [2] recently evaluated the heterogeneity of
depressive symptoms in a large sample of twins, distinguishing
between cognitive and neurovegetative symptoms — a distinction
that has found its way already in the post-MI depression literature
(e.g., [4–6]). Interestingly, in this general population sample, they
found that especially cognitive symptoms within the depression
spectrum were associated with several clinical characteristics,
including higher neuroticism and lower intraversion scores, longer
depression duration and more chronicity. In contrast, previous work
on post-MI depression has suggested that speciﬁcally somatic or
neurovegetative symptoms are associated with poor cardiovascular
outcomes [6], probably via mechanisms linked to cardiovascular
disease such as inﬂammation [7] but also heart rate variability [8].
To those working in psychosomatic medicine, it may not be
surprising that attention to the heterogeneity of depression, in terms
of both its presentation and etiology, has emerged predominantly in
this ﬁeld. Clinicians from consultation-liaison psychiatry and medical
psychology are frequently confronted with medical patients present-
ing with feelings of distress, while often it remains unclear whether
those feelings should be interpreted in the light of an adjustment
disorder or be seen as symptoms of major depressive disorder (MDD),
a somatic reaction to a physiological process or an adaptive
psychological reaction to a life-threatening stressor. Unfortunately,
the Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition, has not been particularly helpful in clarifying this issue by
excluding symptoms as part of depression only when they are thesevier OA license.notoriously overinclusive. This may well be due to their failure to
adequately address the etiological basis of symptoms during a quick
self-report screen [11]. Yet, especially because off the complex
etiology of depression-like symptoms in medical patients, the ﬁeld
of psychosomatic medicinemay play a pioneering role in deconstruct-
ing depression into clinically relevant subtypes.
The conclusion drawn by Poole and colleagues that inﬂammation-
based depression may be an important subtype of depression that is
speciﬁcally prevalent in post-MI populations builds on a large and
heterogeneous body of literature. The authors have performed an
impressive job, as they integrated quite varying parts of the literature,
including animal research, epidemiological studies and intervention
trials, and should be complimented for that. Still, several issues
remain, particularly with respect to how inﬂammation-based depres-
sion may best be dealt with. One of the pillars on which Poole and
colleagues build their argument is that clinical trials evaluating
antidepressant treatment in ACS patients have not been very
successful. Indeed, as only 1%–4% of the improvement in depressive
symptoms may be attributed to the speciﬁc ingredients of antide-
pressants, we are still far away from a truly effective treatment. Yet,
these ﬁgures are not necessarily worse than for unselected patients
(mostly without ACS). For instance, in cardiac patients, the treatment
effects on depressive symptoms after 8 weeks for four antidepressants
(ﬂuoxetine, sertraline, mirtazapine and citalopram) were highly
similar to those reported by Turner and colleagues in unselected
patients using FDA data [11,12]. Similarly, although randomised
comparisons of psychotherapeutical interventions have not always
been very successful, there is not much reason to believe that these
interventions are less effective in patients with ACS than in those
without.
One interesting aspect that Poole and colleagues touched upon is
the reference to the fascinating work by Appels and colleagues on vital
exhaustion. The concept of vital exhaustion was developed ﬁrst as a
form of mental and physical distress preceding ACS, but later on also
as a sequel of ACS with potentially cardiotoxic properties [13]. Of
interest, vital exhaustion was thought to consist of a combination of
feelings of exhaustion and irritation, while depressed mood and
negative cognitions are not frequently present in this syndrome. Its
association with and delineation from depression has received quite
some attention, and the question of whether it represents a form of
distress different from depression has been a pertinent one [14]. Poole
and colleagues' concept of an inﬂammation-based somatic subtype of
60 P. de Jonge / Journal of Psychosomatic Research 71 (2011) 59–60depression is slightly different than vital exhaustion as they consider
it to be a subtype of depression, i.e., fulﬁlling the criteria for MDD. Still,
perhaps insights from the literature on the etiology (e.g., the role of
inﬂammation in vital exhaustion [15]) and treatment of vital
exhaustion (e.g., relaxation therapy, [16]) might help in improving
the efﬁcacy of depression treatment.
I believe that Poole and colleagues are teaching us a valuable
lesson in depression deconstruction, and this may well be a lesson
that goes beyond the ﬁeld of cardiopsychiatry and psychosomatic
research. Only the future can tell whether the identiﬁcation of
inﬂammation-based depression will be truly inﬂuential. Its relevance,
I believe, will depend on the question of whether we will be able to
develop and test interventions that are speciﬁcally effective in
reducing inﬂammation-based symptoms of depression.
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